Crystal Pharmatech specializes in addressing the unique biopharmaceutical challenges of complex molecules, where nearly 70% of R&D candidates face poor water solubility. Our expertise in crystallization and advanced formulation technologies enables us to overcome these bottlenecks through data-driven strategies.
Approximately 70% of small-molecule drugs under research are classified as BCS Class II or IV. For these poorly soluble drugs, we employ a variety of specialized solubilization methods to achieve therapeutic goals.
A cost-effective approach for organic weak acids or bases. Converting these into soluble salts can increase solubility by up to 100x and significantly improve oral bioavailability.
A fluid dynamics-driven process that reduces particle size to the micrometer range. This increases specific surface area, porosity, and surface energy, accelerating dissolution.
The preferred formulation strategy for insoluble compounds. We utilize two primary platforms:
PROTAC (Proteolysis Targeting Chimeras) present "BCS Class IV nightmares" due to high molecular weights (MW > 700), low permeability, and poor solubility. We utilize five core strategies to transform these molecules into viable oral delivery candidates:
Incorporating surfactants or absorption enhancers into the matrix to open tight junctions and move the large molecule across membranes.
Oral delivery of peptides remains a significant challenge due to their size and susceptibility to degradation. Our enabling formulation platform addresses these hurdles through integrated technologies:
We utilize specialized matrix components to facilitate the transport of oral peptides and proteins across the intestinal epithelium.
Self-Microemulsifying Drug Delivery Systems (SMEDDS) are employed to protect the peptide and enhance its absorbability.
Subscribe to be the first to get the updates!
